ProteinConnect: Linking Science, Innovation and Therapeutics (Day 1)
Protein-based therapeutics such as monoclonal antibodies are widely developed and used by the biopharmaceutical industry; in 2023, mAb-based therapeutics represented over half of the Top Ten best-selling drugs of the year, globally, and are one of the fastest growing modalities. However, these large molecules pose unique challenges in relation to sample preparation and analytical characterisation, making robust and fit-for-purpose methods essential to achieve high quality results.
This December, we invite you to connect with fellow scientists to learn more about the latest innovations in Protein analysis at our ProteinConnect Virtual Forum. Through a selection of complementary presentations and resources, our specialists will share insights into the present and future of protein characterisation, including:
- How workflow solutions can address mAb CQA analysis
- Hints and tips for optimising protein bioseparations
- The latest tools and technologies to enhance your protein analysis
- Novel approaches to support online analysis and production of mAbs
- A look to the future – emerging trends in Biopharma analysis
- And much more! agilent ms
Agenda 10 December 2024
10:30 a.m. Approaching The Analysis Of mAbsAnd Protein-based Therapeutics: An Introduction
11:15 a.m. Optimizing Protein Therapeutic Analysis with Agilent Columns: Innovations And Applications
12:15 p.m. Online LC: A Powerful Tool For Process Monitoring During The Production Of mAbs
13:00 p.m. ProteoAnalyzer: Analysis of NIST mAbReference Material By Parallel SDS-Capillary Electrophoresis
